Novo Nordisk A S
NVO-
Novo Nordisk AS jumped 3.4% to $96.34 after the Danish company said it will stop kidney trials earlier because of promising results.
The company's drug therapy Ozempic uses active ingredient semaglutide, which the company also uses in the making of its weight-loss drug Wegovy.
After the Novo Nordisk's news, Davita Inc plunged 18% to $54.58 and Fresenius Medical Care dropped 16.7% to $17.45.
Oct 11, 2023
|
|
| |
|
| Trading Volume | 584,160 |
|
|
199.50 - 87.75 |
| Market Cap Full | $ 0 |
Quarterly +
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Q1 | -58.9% | 1.9% | 24.2% | 17.6% |
| Q2 | - | 127.1% | 13.4% | 1.7% |
| Q3 | - | 127.1% | 3.4% | -43.8% |
| Q4 | - | 127.1% | -21.2% | 12.7% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2026 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - |
| 2025 | |||||||||||
| 1.9 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| 10.9 | 4.4 | 7.3 | -4.8 | 10.9 | 6.7 | -8.1 | 3.4 | - | - | - | -19 |
| 2023 | |||||||||||
| 2.5 | 1.6 | 12.8 | 5 | -3.9 | 0.8 | -0.4 | 15.3 | -51 | 6.1 | 5.5 | 1.6 |
| 2022 | |||||||||||
| -11.6 | 2.6 | 9.6 | 2.2 | -3.2 | 0.9 | 4.2 | -8.6 | -6.1 | 9.2 | 14.5 | 8.6 |
| 2021 | |||||||||||
| -0.4 | 2.6 | -5.6 | 9.7 | 6.8 | 6 | 10.4 | 8.1 | -3.6 | 14.3 | -3 | 5.1 |
EPS
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Q1 | 0.6 | 0.9 | 0.9 |
| Q2 | 0.6 | 0.8 | 0.9 |
| Q3 | 0.7 | 0.9 | 0.8 |
| Q4 | 0 | 0.4 | 0.7 |
| A | 1.99 | 3.05 | 3.3 |